^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Actimab-A (lintuzumab-Ac225) (α radiation emission, CD33-targeted antibody- radioimmunoconjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy.
Published date:
05/25/2023
Excerpt:
CLAG-M in combination with Lintuzumab-Ac225 yielded significantly better clinical outcomes in high-risk populations, particularly in pts previously treated with Ven combinations (median OS 13.8 mo.) and in pts with TP53 mutations (median OS 7.3 mo.), for which recent studies have reported a survival of 4 months or less. The results support further advance in late-stage clinical development of Lintuzumab-Ac225 in combination with CLAG-M in R/R AML, especially in high-risk pts.
Secondary therapy:
CLAG + mitoxantrone
DOI:
10.1200/JCO.2023.41.16_suppl.e19030
Trial ID:
Source:
Title:
65 Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
Published date:
11/03/2022
Excerpt:
...we report results of our Phase I study, and results of pts enrolled in an expansion cohort to characterize PK….Actimab-A+CLAG-M was active in pts with TP53 mutations (ORR 73%)...
DOI:
https://doi.org/10.1182/blood-2022-157827
